ABL-N may induce apoptosis of human prostate cancer cells through suppression of KLF5, ICAM-1 and Stat5b, and upregulation of Bax/Bcl-2 ratio: An in vitro and in vivo study

Zhang,Yanping; Liu,Kailong; Zhang,Yong; Qi,Jinchun; Lu,Baosai; Shi,Chongjun; Yin,Yuewei; Cai,Wenqing; Li,Wei

doi:10.3892/or.2015.4293

ABL-N may induce apoptosis of human prostate cancer cells through suppression of KLF5, ICAM-1 and Stat5b, and upregulation of Bax/Bcl-2 ratio: An in vitro and in vivo study

Authors:
- Yanping Zhang
- Kailong Liu
- Yong Zhang
- Jinchun Qi
- Baosai Lu
- Chongjun Shi
- Yuewei Yin
- Wenqing Cai
- Wei Li
View Affiliations

Affiliations: Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, P.R. China
Published online on: September 18, 2015 https://doi.org/10.3892/or.2015.4293
Pages: 2953-2960

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Identification of novel botanicals that can selectively induce apoptosis and arrest growth of cancer cells without producing cytotoxic effects is highly appreciable for cancer therapy. The present study aimed to investigate the possibility of acetylbritannilactone (ABL) derivative 5-(5-(ethylperoxy)pentan-2-yl)-6-methyl-3-methylene-2-oxo-2,3,3a,4,7,7a‑hexahydroben-zofuran-4-yl2-(6-methoxynaphthalen-2-yl) propanoate (ABL-N) as a therapeutic agent in human prostate cancer and potential mechanisms. Human prostate cancer cells were treated with ABL-N of different concentrations (0, 5, 10, 20, 30 and 40 µmol/l). Cell viability, migration and apoptosis were determined. Activities of caspases were assayed, as well as protein expression of cancer‑related proteins KLF5, Stat5b and ICAM-1 in PC3 cells. The therapeutic effect of ABL-N was further evaluated in our tumor xenografts. ABL-N inhibited growth of prostate cancer cells in a dose-dependent manner, without obvious effect on normal human prostate epithelial PrEC cells. ABL-N administration induced apoptosis of PC3 cells in a dose-dependent manner, along with the enhanced activity of caspases and increased Bax/Bcl-2 ratio. Expression of KLF5, Stat5b and ICAM-1 was significantly downregulated in PC3 cells. Our in vivo study further confirmed that ABL-N significantly inhibited the tumor growth of PC3 cells in the xenograft mouse model. ABL-N induces apoptosis of prostate cancer cells through activation of caspases, increasing the ratio of Bax/Bcl-2, as well as suppression of KLF5, Stat5b and ICAM-1 expressions. The present study indicated that ABL-N may be a potential therapeutic drug for human prostate cancer, and our data supported further studies to explore the therapeutic potential of ABL-N in other types of human cancer.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Matsuda T and Saika K: Comparison of time trends in prostate cancer incidence (1973–2002) in Asia, from cancer incidence in five continents, Vols IV–IX. Jpn J Clin Oncol. 39:468–469. 2009. View Article : Google Scholar : PubMed/NCBI
3	Peng P, Gong Y, Bao P, Ke JZ, Xiang YM, Zhang ML and Zheng Y: Estimates and prediction of prostate cancer incidence, mortality and prevalence in China, 2008. Zhonghua Liu Xing Bing Xue Za Zhi. 33:1056–1059. 2012.In Chinese.
4	Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu HR and Li Q: Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: New hope for cancer patients. Asian Pac J Cancer Prev. 13:5339–5343. 2012. View Article : Google Scholar
5	Bilbro J, Mart M and Kyprianou N: Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Res. 33:4695–4700. 2013.PubMed/NCBI
6	Schmitz-Dräger BJ, Lümmen G, Bismarck E and Fischer C: Prevention strategies for prostate cancer. Minerva Urol Nefrol. 64:225–231. 2012.
7	Samarghandian S, Samini F and Taghavi M: Antiproliferative and cytotoxic properties of honey in human prostate cancer cell line (PC-3): Possible mechanism of cell growth inhibition and apoptosis induction. Afr J Pharm Pharmacol. 8:9–15. 2014. View Article : Google Scholar
8	Hafeez BB, Siddiqui IA, Asim M, Malik A, Afaq F, Adhami VM, Saleem M, Din M and Mukhtar H: A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: Involvement of nuclear factor-kappaB signaling. Cancer Res. 68:8564–8572. 2008. View Article : Google Scholar : PubMed/NCBI
9	Yun JM, Kweon MH, Kwon H, Hwang JK and Mukhtar H: Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145. Carcinogenesis. 27:1454–1464. 2006. View Article : Google Scholar : PubMed/NCBI
10	Fang XM, Liu B, Liu YB, Wang JJ, Wen JK, Li BH and Han M: Acetylbritannilactone suppresses growth via upregulation of krüppel-like transcription factor 4 expression in HT-29 colorectal cancer cells. Oncol Rep. 26:1181–1187. 2011.PubMed/NCBI
11	Rafi MM, Bai NS, Chi-Tang-Ho, Rosen RT, White E, Perez D and Dipaola RS: A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation. Anticancer Res. 25:313–318. 2005.PubMed/NCBI
12	Liu B, Han M, Sun RH, Wang JJ, Zhang YP, Zhang DQ and Wen JK: ABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH₂-terminal kinase activation. Breast Cancer Res. 12:R92010. View Article : Google Scholar
13	Dong L-H, Wen J-K, Liu G, McNutt MA, Miao SB, Gao R, Zheng B, Zhang H and Han M: Blockade of the Ras-extracellular signal-regulated kinase 1/2 pathway is involved in smooth muscle 22 α-mediated suppression of vascular smooth muscle cell proliferation and neointima hyperplasia. Arterioscler Thromb Vasc Biol. 30:683–691. 2010. View Article : Google Scholar : PubMed/NCBI
14	Rao L and White E: Bcl-2 and the ICE family of apoptotic regulators: Making a connection. Curr Opin genet Dev. 7:52–58. 1997. View Article : Google Scholar : PubMed/NCBI
15	Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB and Liu M: Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 68:1843–1850. 2008. View Article : Google Scholar : PubMed/NCBI
16	Bai N, Lai CS, He K, Zhou Z, Zhang L, Quan Z, Zhu N, Zheng QY, Pan MH and Ho CT: Sesquiterpene lactones from Inula britannica and their cytotoxic and apoptotic effects on human cancer cell lines. J Nat Prod. 69:531–535. 2006. View Article : Google Scholar : PubMed/NCBI
17	Wolf BB and Green DR: Suicidal tendencies: Apoptotic cell death by caspase family proteinases. J Biol Chem. 274:20049–20052. 1999. View Article : Google Scholar : PubMed/NCBI
18	Hu W and Kavanagh JJ: Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 4:721–729. 2003. View Article : Google Scholar : PubMed/NCBI
19	Wang X: The expanding role of mitochondria in apoptosis. Genes Dev. 15:2922–2933. 2001.PubMed/NCBI
20	Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ: Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol. 139:1281–1292. 1997. View Article : Google Scholar
21	Adams JM and Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
22	Tafani M, Schneider TG, Pastorino JG and Farber JL: Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition. Am J Pathol. 156:2111–2121. 2000. View Article : Google Scholar : PubMed/NCBI
23	Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H and Nevalainen MT: Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem. 278:27287–27292. 2003. View Article : Google Scholar : PubMed/NCBI
24	Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP and Nevalainen MT: Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res. 11:5863–5868. 2005. View Article : Google Scholar : PubMed/NCBI
25	Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, et al: Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer. 17:481–493. 2010. View Article : Google Scholar : PubMed/NCBI
26	Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Addya S, Fortina P, Dasgupta A, Hyslop T, et al: Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am J Pathol. 176:1959–1972. 2010. View Article : Google Scholar : PubMed/NCBI
27	Yoo NC, Chung HC, Chung HC, Park JO, Rha SY, Kim JH, Roh JK, Min JS, Kim BS and Noh SH: Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. Yonsei Med J. 39:27–36. 1998. View Article : Google Scholar : PubMed/NCBI
28	Li X, Zhang B, Wu Q, Ci X, Zhao R, Zhang Z, Xia S, Su D, Chen J, Ma G, et al: Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells. Int J Cancer. 136:536–546. 2015.
29	Chen C, Bhalala HV, Vessella RL and Dong JT: KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate. 55:81–88. 2003. View Article : Google Scholar : PubMed/NCBI
30	Chen C, Sun X, Ran Q, Wilkinson KD, Murphy TJ, Simons JW and Dong JT: Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene. 24:3319–3327. 2005. View Article : Google Scholar : PubMed/NCBI
31	Tong D, Czerwenka K, Heinze G, Ryffel M, Schuster E, Witt A, Leodolter S and Zeillinger R: Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res. 12:2442–2448. 2006. View Article : Google Scholar : PubMed/NCBI
32	Kwak MK, Lee H-J, Hur K, Park J, Lee HS, Kim WH, Lee KU, Choe KJ, Guilford P and Yang HK: Expression of Krüppel-like factor 5 in human gastric carcinomas. J Cancer Res Clin Oncol. 134:163–167. 2008. View Article : Google Scholar
33	McConnell BB, Bialkowska AB, Nandan MO, Ghaleb AM, Gordon FJ and Yang VW: Haploinsufficiency of Krüppel-like factor 5 rescues the tumor-initiating effect of the Apc^Min mutation in the intestine. Cancer Res. 69:4125–4133. 2009. View Article : Google Scholar : PubMed/NCBI